Shanghai 洛启生物医药技术有限公司 is a clinical-stage biotech focused on developing nanobody (nanobody-based) innovative therapeutics, with an emphasis on respiratory and autoimmune indications. The company says it has established an integrated, systematized development platform and claims end-to-end nanobody drug development capability. It has built five core technology platforms: a rapid nanobody screening platform, a Pichia pastoris CMC process development platform, an inhaled large-molecule drug R&D platform, a nanobody long-acting platform, and a nanobody bispecific platform. 洛启 has constructed a ~7,500+ square meter R&D and production base and a camel breeding base, and completed a 500L Pichia pastoris GMP pilot production workshop. The company was founded in October 2017 and currently employs nearly 90 people. The article reports that 洛启 announced a B++ financing round with the amount undisclosed and named several participating investors. 洛启生物, founded in 2017 and based in Shanghai, focuses on development of inhaled nanobody (nano-antibody) drugs using an inhaled macromolecule drug R&D platform. The company has established R&D, CMC and pilot-production capabilities and built five innovation technology platforms to support inhaled antibody development. It positions itself as the only domestic company with end-to-end development capability for inhaled nanobody therapeutics and emphasizes rapid-onset, high-specificity inhaled candidates. Its lead assets are two inhaled antibody candidates, LQ036 and LQ043, which are advancing toward clinical studies. The company recently completed a financing round exceeding RMB 100 million, improving its near-term financial runway. Planned uses of new capital include supporting Phase II clinical studies of LQ036 and LQ043, expanding the team, and replenishing working capital.

Total raised

$14M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2023